About X4 Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.x4pharma.com/
Frequently Asked Questions
What is the 52-week range for XFOR?
The 52-week high is $4.83 and the 52-week low is $2.8.
What is the P/E ratio for XFOR?
The P/E ratio data is currently unavailable.
What is the dividend yield for XFOR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -63.05%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -568.80%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.96.
Analyst Recommendation Trends
Wall Street analyst consensus for XFOR over the last few months:
Latest XFOR News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on September 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
X4 Pharmaceuticals (XFOR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations. About X4 Pharmaceuticals X4 Pharmac
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the positive outcome of its Type C Meeting with the U.S. Food and Drug Administration (FDA) related to the global 4WARD Phase 3 clinical trial. The pu
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-12 | Volpone John | -24,576 | $4.4445 | $109,228 |
| 2026-08-12 | Craig Adam R | -47,436 | $4.4445 | $210,829 |
| 2026-07-01 | Gold Kelly | +110,000 | - | - |
| 2026-06-30 | KIRSKE DAVID | -8,543 | $4.2641 | $36,428 |
| 2026-05-12 | KIRSKE DAVID | -16,961 | $4.2934 | $72,820 |
| 2026-01-01 | Bridger Gary | +110,000 | - | - |
| 2026-01-01 | de Craecker Francoise | +110,000 | - | - |
| 2026-01-01 | Stewart Murray | +110,000 | - | - |
| 2026-01-01 | WYZGA MICHAEL S | +110,000 | - | - |
| 2025-10-29 | Volpone John | +2,329,154 | - | - |
| 2025-10-29 | Craig Adam R | +2,329,154 | - | - |
| 2025-10-29 | KIRSKE DAVID | +1,552,769 | - | - |
| 2025-10-23 | Craig Adam R | +86,206 | $2.9 | $249,997 |